Welcome to our dedicated page for Varex Imaging SEC filings (Ticker: VREX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Varex Imaging Corporation filings document operating results, financing agreements, governance votes and material events for an X-ray imaging component manufacturer. Recent 8-K reports furnish preliminary quarterly and fiscal-year results, including segment disclosures for the Medical and Industrial businesses and product-demand commentary for CT, cargo systems and detectors.
The company’s regulatory filings also describe its Credit and Guaranty Agreement, secured term loan, revolving credit and delayed draw term loan facilities, subsidiary guarantees, covenants and senior secured note redemption. Governance filings record annual meeting voting results, director elections, auditor ratification, executive compensation votes and officer transition arrangements.
Jay K. Kunkel, a director of Varex Imaging Corp (VREX), sold 3,000 shares of the company's common stock on 08/14/2025 at $10.49 per share. After the sale, he beneficially owned 19,477 shares, reported as direct ownership. The Form 4 disclosure records the transaction and the sale price for each share.
The filing provides a straightforward record of insider liquidity: a director reduced his stake by 3,000 shares while maintaining a mid-sized direct holding in the company. No options, derivative transactions, or other compensatory arrangements are reported.
Varex Imaging Corporation (VREX) Form 144 filing: An insider proposes to sell 3,000 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $31,470. The shares represent restricted stock that vested and were acquired on 02/13/2023 as compensation. The sale is scheduled for approximately 08/14/2025 on NASDAQ. The filer reports 41,500,000 shares outstanding for this class. The filer also disclosed a prior sale of 2,575 shares on 06/18/2025 for gross proceeds of $20,007.75. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Pzena Investment Management LLC has filed Amendment No. 1 to Schedule 13G disclosing a passive ownership position in Varex Imaging Corporation (VREX).
- The value-oriented investment adviser now beneficially owns 4,244,977 common shares, representing 10.2 % of VREX’s outstanding stock.
- Sole voting power: 3,108,798 shares; sole dispositive power: the full 4,244,977 shares. No shares are held with shared voting or dispositive authority.
- The filing is made under Rule 13d-1(b) as an institutional investment adviser (IA), indicating the stake is held in the ordinary course of business and not for the purpose of influencing control.
- All shares are held on behalf of clients; no single client owns more than 5 % of the class.
- The filing date of the event is 30 June 2025; signature is dated 3 July 2025 by Chief Legal Risk & Compliance Officer Steven Coffey.
The >10 % threshold places Pzena among the largest institutional holders of VREX, potentially increasing trading liquidity and indicating external confidence in the company’s valuation, although the passive 13G designation suggests no activist intent.
Director Jay K. Kunkel of Varex Imaging Corp (VREX) reported a significant insider transaction on June 18, 2025. The filing discloses that Kunkel sold 2,575 shares of common stock at a price of $7.77 per share, resulting in a total transaction value of approximately $20,007.
Following this disposition, Kunkel's direct ownership position decreased to 22,477 shares of Varex Imaging common stock. The transaction was executed as a straight sale (Transaction Code: S) and was reported within the required filing deadline.
Key transaction details:
- Transaction Type: Direct sale of common stock
- Shares Sold: 2,575 at $7.77 each
- Remaining Direct Holdings: 22,477 shares
- Filing Status: Form 4 filed timely on June 20, 2025